- Novartis AG
- GlaxoSmithKline PLC
- Center of Excellence for External Drug Discovery
- Enlight Biosciences LLC
- Eli Lilly & Co.
- Pfizer Inc.
- Merck & Co. Inc.
- Amgen Inc.
- Biogen Inc.
- Jubilant Life Sciences Ltd.
- Piramal Enterprises Ltd.
- Ranbaxy Laboratories Ltd.
- Daiichi Sankyo Co. Ltd.
- Suven Life Sciences Ltd.
- Hutchison MediPharma Ltd.
- Hutchison China MediTech Ltd.
- Bristol-Myers Squibb Co.
- AstraZeneca PLC
- Quintiles Transnational Holdings Inc.
- Pharmaceutical Product Development Inc.
- Alexza Pharmaceuticals Inc.
- OxiGene Inc.
- Enlight Biosciences formed with $39mm in funding
- Lilly and Jubilant form JV; Jubilant later takes over
- Suven and Lilly in early-stage CNS research deal
- Piramal agrees to develop candidates for Lilly
- Eli Lilly and Hutchison MediPharma enter development pact
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
- BMS, Pfizer work together on Phase III antithrombotic
- TPG-Axon provides Eli Lilly with funds for Alzheimer's trials
- Alexza forms financing vehicle to support CNS agents
- Symphony financing to support OxiGene cancer, eye programs
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.